You are here:

fluticasone furoate / vilanterol (Relvar Ellipta®)

Advice

following a full submission:

fluticasone furoate / vilanterol (Relvar Ellipta®) is accepted for use  within NHS Scotland.

Indication under review: the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.

There was no statistically significant difference between fluticasone furoate/vilanterol 92/22 micrograms daily and another inhaled corticosteroid/long acting beta2-agonist combination (ICS/LABA)  inhaler for 0 to 24 hour serial weighted mean forced expiratory volume in one second, at 24 weeks.

Some alternative ICS/LABA combination inhalers are available at a lower daily cost.

Drug Details

Drug Name: fluticasone furoate / vilanterol (Relvar Ellipta®)
SMC Drug ID: 966/14
Manufacturer: GlaxoSmithKline UK Ltd
Indication: For the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
BNF Category:
Sub Category: 3.2 Corticosteroids
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 June 2014

Back